Pancreatic ductal adenocarcinoma: emerging therapeutic strategies.

Show simplified metadata
dc.contributor.authorOsei-Bordom, Daniel C
dc.contributor.authorSerifis, Nikolaos
dc.contributor.authorBrown, Zachary J
dc.contributor.authorHewitt, D Brock
dc.contributor.authorLawal, Gbemisola
dc.contributor.authorSachdeva, Gagandeep
dc.contributor.authorCloonan, Daniel J
dc.contributor.authorPawlik, Timothy M
dc.contributor.departmentSurgeryen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.trustauthorOsei-Bordom, Daniel C
dc.date.accessioned2023-10-20T11:02:03Z
dc.date.available2023-10-20T11:02:03Z
dc.date.issued2022-07-07
dc.description.abstractThe seventh leading cause of cancer-related death globally, pancreatic ductal adenocarcinoma (PDAC) involves the exocrine pancreas and constitutes greater than 90% of all pancreatic cancers. Surgical resection in combination with systemic chemotherapy with or without radiation remains the mainstay of treatment and the only potentially curative treatment option. While there has been improvement in systemic chemotherapy, long-term survival among patients with PDAC remains poor. Improvement in the understanding of tumorigenesis, genetic mutations, the tumor microenvironment (TME), immunotherapies, as well as targeted therapies continued to drive advances in PDAC treatment. We herein review the TME, genetic landscape, as well as various metabolic pathways associated with PDAC tumorigenesis relative to emerging therapies.en_US
dc.identifier.citationOsei-Bordom DC, Serifis N, Brown ZJ, Hewitt DB, Lawal G, Sachdeva G, Cloonan DJ, Pawlik TM. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Surg Oncol. 2022 Aug;43:101803. doi: 10.1016/j.suronc.2022.101803. Epub 2022 Jul 7en_US
dc.identifier.doi10.1016/j.suronc.2022.101803
dc.identifier.eissn1879-3320
dc.identifier.issn0960-7404
dc.identifier.pmid35830772
dc.identifier.urihttp://hdl.handle.net/20.500.14200/2638
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/journal/surgical-oncologyen_US
dc.rightsCopyright © 2022 Elsevier Ltd. All rights reserved.
dc.source.beginpage101803
dc.source.countryNetherlands
dc.source.endpage
dc.source.journaltitleSurgical Oncology
dc.source.volume43
dc.subjectSurgeryen_US
dc.titlePancreatic ductal adenocarcinoma: emerging therapeutic strategies.en_US
dc.typeArticle
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
UHB Oncology